Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Monocentric study composed by 2 steps : 1. First step is a phase I with the aim of establish the recommended dose of mirdametinib administration (2 or 4 mg twice a day for 7 or 14 days per cycle for the 4 first of carboplatin/pemetrexed/pembrolizumab treatment) 2. Second step is a non comparative randomized (2:1) phase II trial testing the recommended dose of mirdametinib administration. The aim is the efficacy and safety of short course of mirdametinib treatment for the 4 first cycles of the carboplatin/pemetrexed/pembrolizumab treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie zaawansowanego raka płuc (typu non-squamous non-small cell)
- •Wiek powyżej 18 lat
- •Brak wcześniejszego leczenia tego typu raka (chemioterapia adjuwantna możliwa powyżej 12 miesięcy)
- •Dobra ogólna kondycja zdrowotna (status ECOG 0 lub 1)
- •Spodziewana długość życia co najmniej 6 miesięcy
- •Wynik testu PD-L1 poniżej 50%
- •Możliwość zobaczenia nowotworu na badaniach obrazowych (tomografia, rezonans)
- •Waga powyżej 30 kg
✗ Disqualifies
- •Zaburzenia rytmu serca lub problemy z funkcją serca
- •Niezadowalające funkcje wątroby, nerek lub szpiku kostnego
- •Przedłużony QTc na elektrokardiogramie (powyżej 450 ms)
- •Skrócona spodziewana długość życia poniżej 6 miesięcy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Centre Georges-François Leclerc
Dijon, France
Trial contact
François FG GHIRINGHELLI, Professor
Emilie ER REDERSTORFF, Project manager
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.